Provectus Biopharmaceuticals, Inc. · OTC:PVCT
Provectus Biopharmaceuticals — Corporate Update (November 2024)
19 slides from Provectus Biopharmaceuticals's corporate update, Nov 14, 2024
Slide 1: Provectus Biopharmaceuticals, November 14, 2024
NOVEMBER 14, 2024 O provectus biopharmaceuticals
Slide 2: Today's Agenda
Today’s Agenda Host: Alyssa Barry, Alliance Advisors IR, President Opening Remarks: Ed Pershing, Provectus, Chairman and Chief Executive Officer Company Updates: Dominic Rodrigues, Provectus, Vice Chairman and President Q&A: Alyssa (Moderator), Ed, and Dominic Closing Comments: Ed Thank You & Sign-o
Slide 3: Forward-Looking Statements
Forward-Looking Statements The information provided in this presentation may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information an
Slide 4: Opening Remarks
Opening Remarks (Ed) Value * Provectus’s value will be determined by the unique capabilities of the rose bengal sodium (RBS) molecule, the Company’s proprietary synthesis process for manufacturing pharmaceutical-grade RBS API, and the potential, numerous, global market opportunities to address diffe
Slide 5: Opening Remarks (cont'd)
Opening Remarks (cont’d) (Ed) Business model ¢ We believe that a dynamic and multi-faceted business model for Provectus is essential to fully realizing RBS’s capabilities and the Company’s intrinsic value—and consequently Provectus’s market capitalization * This business model may have to be tailore
Slide 6: Injectable solid tumor cancers: Clinical-stage PV-10
Injectable solid tumor cancers: Clinical-stage PV-10 (Dominic) Metastatic pancreatic ductal adenocarcinoma (mPDAC) * Provectus’s current goal is to secure an FDA Type C meeting in 1H25 for the clearance of the Company-sponsored mPDAC Phase 1 clinical trial program, enabling patient enrollment at Mof
Slide 7: Ophthalmology: Clinical-stage PV-305 & Launching a clinical-stage startup company
Ophthalmology: Clinical-stage PV-305 & Launching a clinical-stage startup company (Dominic) Overview * Provectus is forming a clinical-stage biotechnology start-up company to commercialize innovative ocular research from the University of Miami’s Miller School of Medicine’s Bascom Palmer Eye Institu
Slide 8: Ophthalmology (cont'd)
Ophthalmology (cont’d) (Dominic) Deal structure * NewCo’s seed round would be up to $3 million (for common stock) in three milestone-based funding tranches; post-money valuations would range from $20 million to ~$33 million * The funding would support completing a pre-IND submission meeting to clari
Slide 9: Ophthalmology (cont'd)
Ophthalmology (cont’d) (Ed) An opportunity for Provectus monetization * NewCo embodies Provectus’s dynamic business model * Establishing and spinning out a clinical-stage, ophthalmology-focused, biotechnology company—as a majority-owned affiliate of Provectus—aligns well with the Company’s strategic
Slide 10: Manufacturing
Manufacturing G (Dominic) PV-10 * Provectus is currently working with our CDMO partner to produce a new Clinical supply of PV-10 forinjectable solid tumor cancers PV-305 * The Company is also working with this CDMO to produce an initial clinical supply of PV-305 for ophthalmology CMC * Consistently
Slide 11: Veripure
Veripure G (Dominic) Trademark * Provectus’s goal for developing this brand and pursuing its trademark is to definitively establish the Company’s proprietary technology and processes for producing pharmaceutical-grade RBS API at near-100% purity Open-source RBS medical research * Provectus aims to b
Slide 12: Veripure (cont'd)
Veripure (cont’d) G (Ed) Other technologies * We believe that Provectus’s collaborative philosophy of open-source research, together with our business culture, can facilitate and support the addition of other medical science and technology to the Company’s platform Business model * Veripure and Prov
Slide 13: Other research
Other research G (Dominic) Dermatology & Wound healing: Clinical-stage PH-10 * Provectus anticipates the initiation of a large animal study in 1Q25—a collaborative effort between Company research programs at The Rockefeller University (TRU) in New York City and the University of Texas Medical Branch
Slide 14: Other research (cont'd)
Other research (cont’d) (Dominic) Canine cancers The effort by the University of Tennessee College of Veterinary Medicine to establish a foundational non-clinical research dataset of in vitro activity and in vivo safety of PV-10 for treating soft tissue sarcomas in dogs has been surprisingly ineffic
Slide 15: Other research (cont'd)
Other research (cont’d) (Dominic) Pending medical journal articles * Head and neck SCC by Moffitt (non-clinical) * mNET by Australian clinicians (clinical) * Tissue regeneration and repair by the University of Nevada, Las Vegas (non-clinical)
Slide 16: Q&A
Q&A (Alyssa [Moderator], Ed, and Dominic)
Slide 17: Closing Comments
Closing Comments G (Ed) Value * Provectus’s value will be defined by RBS’s unique capabilities, the Company’s proprietary molecular manufacturing method, and opportunities to expand our pipeline-in-a-platform Pharmaceutical-grade RBS * Provectus is currently the world’s sole provider of pharmaceutic
Slide 18: Thank You!
Thank You! Opa Visit our Website Contact Us: investorrelations@pvct.com www.ProvectusBio.com NT Vilu Joined OTCQB 10/2016 iv} Company Verified Profile 09/2024 U Transfer Agent Verified &* Independent Directors OTCQB Venture Index
Slide 19: Acronyms
Acronyms G API = active pharmaceutical ingredient FDA = U.S. Food and Drug Administration RB PDAT = rose bengal photodynamic antimicrobial therapy RBS PDAT = rose bengal sodium photodynamic antimicrobial therapy NIH = National Institutes of Health REAGIR = Rose Bengal Electromagnetic Activation with
Provectus Biopharmaceuticals — Corporate Update (November 2024) on 6ix